Celldex Therapeutics Inc (CLDX)

2.40
0.01 0.42
NASDAQ : Health Care
Prev Close 2.39
Open 2.39
Day Low/High 2.36 / 2.42
52 Wk Low/High 2.96 / 25.60
Volume 1.08M
Avg Volume 1.84M
Exchange NASDAQ
Shares Outstanding 125.10M
Market Cap 295.25M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Celldex Therapeutics Presents Phase 1 Study Of Varlilumab And Opdivo® At 2017 ASCO Annual Meeting

Early signs of clinical activity without increased toxicity observed

Celldex Presents Promising Overall Survival Data From Phase 2 Study Of Single-agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma

Combination study with checkpoint inhibitor currently enrolling; data from combination arm with varlilumab anticipated in fall of 2017

First Week Of November 17th Options Trading For Celldex Therapeutics (CLDX)

Investors in Celldex Therapeutics, Inc. saw new options begin trading this week, for the November 17th expiration.

Celldex Provides Corporate Update And Reports Full Year 2016 Results

Conference Call Scheduled for 4:30 p.m. ET Today

First Week of CLDX March 17th Options Trading

Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the March 17th expiration.

Are People Finally Noticing?

Recognition of the market's inertia seems to be growing.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Celldex Presents Data On CDX-1140, A Novel CD40 Agonist Antibody For Hematologic And Solid Malignancies, At The American Society Of Hematology (ASH) Annual Meeting

Celldex Presents Data On CDX-1140, A Novel CD40 Agonist Antibody For Hematologic And Solid Malignancies, At The American Society Of Hematology (ASH) Annual Meeting

Additional investigator-sponsored presentations on varlilumab, CDX-301 and CDX-1401 also at ASH

Commit To Buy Celldex Therapeutics At $3, Earn 23.3% Using Options

Commit To Buy Celldex Therapeutics At $3, Earn 23.3% Using Options

Investors considering a purchase of Celldex Therapeutics, Inc. shares, but cautious about paying the going market price of $4.17/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

Celldex Expands Antibody And Immuno-Oncology Portfolio With The Acquisition Of Kolltan Pharmaceuticals

Celldex Expands Antibody And Immuno-Oncology Portfolio With The Acquisition Of Kolltan Pharmaceuticals

--Conference call to be held at 4:30 p.m. Eastern Time today--

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) reported a narrower loss than analysts had anticipated for the 2016 second quarter after Monday's closing bell.

Celldex Therapeutics (CLDX) Is Strong On High Volume Today

Celldex Therapeutics (CLDX) Is Strong On High Volume Today

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

Celldex Reports Second Quarter 2016 Results

Celldex Reports Second Quarter 2016 Results

Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time